BRIEF-IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Reuters

Sep 29

BRIEF-<a href="https://laohu8.com/S/IOBT">IO Biotech</a> Provides Update Following Pre-BLA Meeting with FDA

Sept 29 (Reuters) - IO Biotech Inc IOBT.O:

IO BIOTECH PROVIDES UPDATE FOLLOWING PRE-BLA MEETING WITH FDA
IO BIOTECH INC - FDA RECOMMENDS IO BIOTECH NOT SUBMIT BLA FOR IOB-013
IO BIOTECH INC - PLANS NEW STUDY FOR CYLEMBIO IN MELANOMA
IO BIOTECH INC - TO REDUCE WORKFORCE BY ABOUT 50%
IO BIOTECH INC - EXPECTS $1.0 MILLION-$1.5 MILLION CHARGE IN Q3 2025

Source text: ID:nGNX7J20NH

Further company coverage: IOBT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571238757"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571238757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571238757?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571238757","market":"fut","top_or_hot":-1,"title":"BRIEF-IO Biotech Provides Update Following Pre-BLA Meeting with FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/IOBT\">IO Biotech</a> Provides Update Following Pre-BLA Meeting with FDA</title></head><body><p><span>Sept 29 (Reuters)</span><span> - </span>IO Biotech Inc <span>IOBT.O</span>:</p><ul><li><p>IO BIOTECH PROVIDES UPDATE FOLLOWING PRE-BLA MEETING WITH FDA</p></li><li><p>IO BIOTECH INC - FDA RECOMMENDS IO BIOTECH NOT SUBMIT BLA FOR IOB-013</p></li><li><p>IO BIOTECH INC - PLANS NEW STUDY FOR CYLEMBIO IN MELANOMA</p></li><li><p>IO BIOTECH INC - TO REDUCE WORKFORCE BY ABOUT 50%</p></li><li><p>IO BIOTECH INC - EXPECTS $1.0 MILLION-$1.5 MILLION CHARGE IN Q3 2025</p></li></ul><p>Source text: <span>ID:nGNX7J20NH</span></p><p>Further company coverage: <span>IOBT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-IO Biotech Provides Update Following Pre-BLA Meeting with FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-IO Biotech Provides Update Following Pre-BLA Meeting with FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-29 19:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/IOBT\">IO Biotech</a> Provides Update Following Pre-BLA Meeting with FDA</title></head><body><p><span>Sept 29 (Reuters)</span><span> - </span>IO Biotech Inc <span>IOBT.O</span>:</p><ul><li><p>IO BIOTECH PROVIDES UPDATE FOLLOWING PRE-BLA MEETING WITH FDA</p></li><li><p>IO BIOTECH INC - FDA RECOMMENDS IO BIOTECH NOT SUBMIT BLA FOR IOB-013</p></li><li><p>IO BIOTECH INC - PLANS NEW STUDY FOR CYLEMBIO IN MELANOMA</p></li><li><p>IO BIOTECH INC - TO REDUCE WORKFORCE BY ABOUT 50%</p></li><li><p>IO BIOTECH INC - EXPECTS $1.0 MILLION-$1.5 MILLION CHARGE IN Q3 2025</p></li></ul><p>Source text: <span>ID:nGNX7J20NH</span></p><p>Further company coverage: <span>IOBT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOBT","symbol_name":"IO Biotech, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA4ZDH4T:1","article_id":"2571238757","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571238757","pubTimestamp":1759144286,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-IO Biotech Provides Update Following Pre-BLA Meeting with FDASept 29 (Reuters) - IO Biotech Inc IOBT.O:IO BIOTECH PROVIDES UPDATE FOLLOWING PRE-BLA MEETING WITH FDAIO BIOTECH INC - FDA RECOMMEND","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOBT":"IO Biotech, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-IO Biotech在与FDA举行BLA前会议后提供更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOBT":0.9},"content_text":"BRIEF-IO Biotech Provides Update Following Pre-BLA Meeting with FDASept 29 (Reuters) - IO Biotech Inc IOBT.O:IO BIOTECH PROVIDES UPDATE FOLLOWING PRE-BLA MEETING WITH FDAIO BIOTECH INC - FDA RECOMMENDS IO BIOTECH NOT SUBMIT BLA FOR IOB-013IO BIOTECH INC - PLANS NEW STUDY FOR CYLEMBIO IN MELANOMAIO BIOTECH INC - TO REDUCE WORKFORCE BY ABOUT 50%IO BIOTECH INC - EXPECTS $1.0 MILLION-$1.5 MILLION CHARGE IN Q3 2025Source text: ID:nGNX7J20NHFurther company coverage: IOBT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}